CLVS - Clovis Oncology stock rises on positive data from Phase 3 ovarian cancer treatment trial

Clovis Oncology (NASDAQ:CLVS) said on Monday its therapy Rubraca significantly improved progression-free survival compared with placebo in women with advanced ovarian cancer in a late-stage trial. Stock up 6.3% before the bell. The trial, dubbed Athena-Mono, met its primary endpoint, which showed Rubraca versus placebo improved progression-free survival by investigator assessment in both populations in the primary efficacy analyses - HRD-positive and all patients randomized. The median progression-free survival for the HRD-positive patient population treated with the therapy was 28.7 months compared to 11.3 months among those who received placebo, the company said. While, the median progression-free survival for all patients was 20.2 months compared to 9.2 months among those who received placebo. The results from another trial called Athena-Combo - rucaparib plus nivolumab versus rucaparib - is expected in Q1 2023.

For further details see:

Clovis Oncology stock rises on positive data from Phase 3 ovarian cancer treatment trial